Get the Stockscreener App
4.04
5.39%
-0.23
After Hours:
4.01
-0.03
-0.74%
Nervgen Pharma Corp stock is traded at $4.04, with a volume of 92,632.
It is down -5.39% in the last 24 hours and up +5.48% over the past month.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$4.27
Open:
$4.29
24h Volume:
92,632
Relative Volume:
1.22
Market Cap:
$320.02M
Revenue:
-
Net Income/Loss:
$-18.50M
P/E Ratio:
-15.60
EPS:
-0.259
Net Cash Flow:
$-11.89M
1W Performance:
-3.35%
1M Performance:
+5.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.98
$4.3649
1-Week Range:
$3.80
$4.39
52-Week Range:
$3.73
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.04 | 338.24M | 0 | -18.50M | -11.89M | -0.259 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen appoints regulatory and patient advocacy executives - Investing.com Nigeria
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Australia
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
How NervGen Pharma Corp. (9UA) stock reacts to weak economy2025 Dividend Review & Low Risk High Win Rate Picks - mfd.ru
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - The Manila Times
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Nigeria
Why NervGen Pharma Corp. (9UA) stock stays on buy listsInsider Selling & High Conviction Investment Ideas - mfd.ru
Why NervGen Pharma Corp. (9UA) stock could be next leader2025 Price Momentum & Growth Focused Stock Pick Reports - mfd.ru
NervGen Pharma to Present at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium - marketscreener.com
NervGen Pharma Corp. Announces CFO Changes, Effective March 15, 2026 - marketscreener.com
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - The Manila Times
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
Adam Rogers Appointed CEO of NervGen Pharma to Advance Spinal Cord Injury Treatment Efforts - geneonline.com
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - GlobeNewswire
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):